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Abstract
The ecosystem of how the pharmaceutical industry acquires data, transforms these data into
tangible knowledge, and derives valuable insights throughout the process, is highly complex.
Data, information, knowledge, and the resulting insights, are necessary to support decisionmaking, manage risk, problem solve, ensure product realisation, enable continual
improvement, and enhance operational effectiveness. Building on the fundamental concepts
established in the well-known Data Information Knowledge Wisdom (DIKW) hierarchy, this
paper reviews the basic concepts involved in the DIKW pathway and begins to relate these
concepts to both established capabilities (e.g., PAT), existing requirements (e.g., data
integrity), and emerging trends in the industry (e.g., industry 4.0). This paper introduces
additional research studies which the Pharmaceutical Regulatory Science Team (PRST) is
considering, regarding how one might apply systems thinking concepts to develop a
framework which will enable key stakeholders (Industry, Regulatory and Academia) to better
relate the many elements of this ecosystem. The paper concludes by identifying preliminary
foundational principles which could form the basis of such a framework, coined by the
authors as ‘The pharmaceutical knowledge ecosystem’, and makes the case for further
exploration of this concept.

Introduction
In general, Knowledge Management (KM) is the process of improving business performance
by increasing efficiency, building more robust processes, facilitating continual improvement,
and creating an engaged knowledge workforce. In the pharmaceutical sector, such knowledge
could be pharmacovigilance data, or product and process information. KM is a
multidisciplinary and cross functional approach, designed to achieve target metrics and other
company objectives. It includes dimensions of people, process, content, and technology
(BPOG, 2017).
A long-standing framework in the discipline of information science is the Data, Information,
Knowledge, Wisdom (DIKW) hierarchy shown in Figure 1 (Rowley, 2007).
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Figure 1 - DIKW Hierarchy

This framework provides a simple visual how data, information, knowledge, and wisdom are
related. In context of the DIKW, hierarchy is used to aid the articulation of knowledge. Its
development is often credited to Ackoff, as described by Rowley. The following definitions of
the terms are useful to consider (Rowley, 2007):
•

Data: Symbols that represent the properties of objects and events.

•

Information: Processed data, such that the processing results in increasing the data’s
usefulness e.g., data with context.

•

Knowledge: As defined by the Cambridge dictionary (Cambridge University Press,
2011), ‘awareness, understanding or information that has been obtained by
experience or study, and that is either in a person’s mind or possessed by people.
However, in the content of an organisation, knowledge can be a combination of
context (explicit knowledge), information, as well as tacit knowledge’

•

Wisdom: Wisdom is the ability to increase effectiveness. Wisdom adds value, which
requires the mental function that we call judgement.

While the DIKW hierarchy is helpful, it is not necessarily pragmatic in application in the current
pharmaceutical technology environment. Kane, as part of her PhD research, proposed an
alternative to the above DIKW hierarchy, replacing wisdom with insights, shown below in
Figure 2 (Kane, 2018).

Figure 2 - Data-Information-Knowledge-Insights (as adapted by Kane)
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Wisdom is widely agreed to be a “uniquely human” characteristic, whereas insights take
account of current technological advances where data transformation can lead to insights.
While insights may be derived by people with knowledge and experience, they may also be
derived from computing or machine learning models that identify trends and correlations
previously not possible to see with experience alone.
This paper explores Data, Information, Knowledge, and Insights, and how these required
elements in the pharmaceutical development and manufacturing sector can be utilised to
develop, continually improve, transfer, monitor and sustain pharmaceutical products.

Thought Models for connecting data to understanding
While it is useful to replace wisdom with insights in the DIKW hierarchy, on reflection, the
successive goal is to achieve understanding. Whereas insights could be regarded as discrete,
understanding represents a holistic comprehension – a state of mastery for a given domain
or topic. This state of mastery could manifest, for example, as a mechanistic understanding
of a complex chemical reaction or as an accurate predictive model for the relationship
between process parameters and their impact on final product quality attributes. In each
case, there is a progression from being naïve to developing understanding (i.e., a state of
mastery) based on accumulated data, information, knowledge, and insights as depicted in
Figure 3 below (Lipa, 2020).

Figure 3 - Data-Information-Knowledge-Insight & Understanding (as adapted by Lipa)

Having mastered this progression of data to information to knowledge to insights and
understanding – it presents the opportunity that one will be able to make informed and
effective decisions, based on accumulated evidence, as provided by the underlying structure.
Another model that depicts this concept is published in the Pharmaceutical Manufacturing
Technology Centre (PMTC), Data Analytics Good Practice Guide (PMTC, 2020) as shown below
in Figure 4.
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Figure 4 - PMTC model for data to understanding

The PMTC model includes several features:
• The progression from data infrastructure through data access to data visualisation
(through the green dotted ovals), and ultimately linking to process understanding
(through the red dotted ovals), then ultimately applied through knowledge
management and QRM.
• Also, on this diagram the x-axis represents the concept of data context, and that there
is a positive correlation between data context and the level of understanding: As you
increase context (e.g., through data analysis), you can increase understanding.
• In addition, on this diagram you see the transitioning from producers of data (the
practitioners, scientists and analysts) to users or consumers (the decision-makers and
end-users). The producers on the left of the diagram involved with generating the
data and its preliminarily analysis and the consumers more to the right of the diagram,
involved with consuming the data to create knowledge and understanding, and
ultimately apply to make decisions.

KM and QRM as the foundation of the PQS
In 2008, ICH Q10 described effective Pharmaceutical Quality System (PQS) (ICH, 2008). The
three objectives of the PQS defined in ICH Q10 are:
•
•
•

Achieve product realisation
Establish and maintain a state of control
Facilitate continual improvement.

ICH Q10 identified Knowledge Management (KM) and Quality Risk Management (QRM) as the
two enablers of an effective Pharmaceutical Quality System as depicted on the ICH Q10 PQS
process model shown below in Figure 5. (ICH, 2008)
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Figure 5 - PQS as defined by ICH Q10

ICH Q9 presented the QRM process flow model (shown below in Figure 6) outlining how to
manage risk to the patient, based on the best scientific knowledge, thus enabling effective
decision making.

Figure 6 - QRM process model as defined in ICH Q9

While the ICH Q9 process flow model is well known – perhaps iconic – what was lacking was
a KM process flow model to outline how to ensure best scientific knowledge is available to
support PQS realisation and effective decision-making. A contributing factor may be that risk
management has been around for more than 70 years as management science, while KM only
surfaced in the last 20 years or so, thus the level of guidance on risk management from other
industries far exceeds the guidance on knowledge management. Lipa, as part of his PhD
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research, proposed a KM process flow model shown below in Figure 7, to enhance the
practical understanding of KM as the complimentary PQS enabler to QRM (Lipa, 2021a).
Illustrative processes
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Figure 7 - Knowledge Management Process Model

While this KM process flow diagram is explained in detail in Lipa et al. 2020, what is important
for this paper is to understand that it incorporates the elements of the definition of KM
proposed in ICH Q101 and further enhances it by:
•
•
•
•

Highlighting the need for knowledge to flow and to subsequently be applied
Featuring the need for KM practices to facilitate the management of both explicit and
tacit2 knowledge
Providing channels for knowledge communication, exchange and sharing, which is
how the organisation interacts with the knowledge base that exists (both explicit and
tacit), supported by a knowledge culture
Identifying the basis of prior knowledge by depicting specific steps which must occur
for knowledge to be available, with appropriate context, for future application (e.g.,
knowledge capture, identification, review, and analysis).

1

A systematic approach to acquiring, analysing, storing, and disseminating information related to products,
manufacturing processes and components
2
Explicit knowledge is defined as codified knowledge, typically documents, whereas tacit knowledge is
knowledge in the heads of people, often referred to as “know how”
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Linking Data, Knowledge and Risk
The PMTC Good Practice Guide for Data Analytics indicates that:
“Data becomes knowledge through the vehicle of data analytics. Knowledge is a
critical milestone that can be integrated and built upon to develop
process understanding. Value is realised through such understanding.”
Reflecting on this and returning to the simple hierarchy of data, information, knowledge,
insight and understanding, the authors propose that this framework is foundational to many
processes and activities common in the pharmaceutical industry. In considering development
studies, QRM, continuous process verification (CPV), change management, technology
transfer and more – each of these processes and activities generate data and information,
which presents the opportunity to create knowledge, insights and understanding by
progression “up” the framework. This concept is shown by insertion of the hierarchy in the
KM Process flow diagram in Figure 8 below.

Figure 8 - Data inputs to Knowledge Management Process Model

However, to effectively do this, we need to vertically integrate the hierarchy by having
processes and steps in place to be able to progress “upwards” in the hierarchy, from data
through information to knowledge, thus ultimately reaching insights and understanding. This
does not happen by chance: one needs a strategy to achieve this integration. Work on
developing such a strategy is on-going and will be published in subsequent articles by the
authors.
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Returning to the PQS and ICH Q10 which identified Knowledge Management (KM) and Quality
Risk Management (QRM) as the two enablers of an effective Pharmaceutical Quality System,
both KM and QRM require data and information and knowledge (both tacit and explicit) as
inputs. Between 2008 to 2020, the two enablers were in the main treated separately, until
Lipa (Lipa, 2021a) in his PhD research linked them in the Risk-Knowledge Infinity (RKI) Cycle.
The RKI Cycle highlighted the key activities of the interaction between QRM and KM, as shown
in Figure 9 below. (Lipa et al., 2020)

Figure 9 - Risk-Knowledge Infinity Cycle as applied to ICH Q10

An important underlying principle is that risk and knowledge are inversely proportional, that
is, increased knowledge leads to decreased uncertainty and therefore decreased risk (ISPE,
2021). Given this realisation, the RKI Cycle proposed a continuous pathway for knowledge
(both tacit and explicit) to inform risk (nodes 6 and 1). Furthermore, knowledge is recognised
as an output from QRM, and can be managed through effective KM (nodes 3 and 4). Both
QRM (node 2) and KM (node 5) are enabled via their respective processes where suitable
methods and tools are utilised to decrease risk by using increasing knowledge as it emerges.
The key features of the RKI cycle are that:
•
•
•
•

Knowledge is both an input to and an output of risk management
Knowledge has an inverse relationship with risk: the more knowledge one has, the
less uncertainty and therefore, the less risk
The Concept of flow: knowledge flows to inform risk, and risk informs new knowledge
(and gaps in knowledge)
The cycle is continuous & perpetual.

All the interrelated concepts in play as discussed in this paper are depicted in the word cloud
below (Figure 10):
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8

Adams et al.: Exploring Pathways from Data to Knowledge to Insights in the Pharmaceutical Industry

Figure 10 - Interrelated concepts presented in this paper

There are various disciplines involved which are largely disconnected in practice currently,
therefore, it is useful to consider them through the lens of Systems Thinking3, and see the
opportunity for them to work together for the benefit of the patient. Indeed, one can envision
the relationship between knowledge and risk as an ecosystem informing each other. (Senge
et al., 1999; The MITRE Corporation, 2010)
For example, it is clear that over time in the pharmaceutical life cycle, the aim is to grow
knowledge and to minimise risk, thus, considering specifically node 4 on the RKI cycle,
(acquire, grow, capture and retain new knowledge), one could envisage the DIK(IU)4 hierarchy
integrated here as shown below in Figure 11 (Lipa, 2021b).

Figure 11 - DIK(IU) as a means to acquire, grow, capture and retain new knowledge

3

https://www.mitre.org/publications/systems-engineering-guide/enterprise-engineering/comprehensiveviewpoint/systems-thinking
4
Data, information, knowledge, insights/understanding
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Then returning to ICH Q10 and the PQS, this leads the two enablers of QRM and KM not just
be united with each other, but more holistically – as a system – with data, information,
knowledge, insights and optimally understanding – in a re-envisioned model of the PQS as
shown Figure 12 (Lipa, 2021b).

Figure 12 - DIK(IU) as a means to grow knowledge, inform risk and improve PQS

The Pharmaceutical Knowledge Ecosystem
In 2019 a further ICH guidance was published, ICH Q12, Technical and regulatory
considerations for pharmaceutical product lifecycle management (ICH, 2019). In it the
following was observed:
“An effective PQS as described in ICH Q10 and in compliance with regional GMP
requirements where the application is filled, is necessary across the entire supply chain
and product lifecycle to support use of the tools described in this guideline. It includes
appropriate change management, enabled by knowledge management, and
management review.” (ICH, 2019)
As discussed, researchers believe that Data Management and Knowledge Management are
adjacencies – and part of the ecosystem. Today they are largely looked at independently –
but should be examined as part of a systems approach so they are co-optimized. When this
occurs the ability to capture, store and provide visibility of product knowledge is critical to
enable effective development and manufacture of medicinal product. This ability to capture,
store and provide visibility of product knowledge referred to as the ‘Pharmaceutical
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Knowledge Ecosystem’, by the authors, is essential to support continual improvement and
post approval change management across the pharmaceutical product lifecycle.

Closing thoughts on transforming data into knowledge and insights
Before COVID 19 there was a measured rise of a geographically dispersed and increasingly
mobile workforce which created new barriers to collaboration. Today’s transformation into
remote ways of working has led to traditional ways of collaborating, such as working with
colleagues that sit nearby, no longer reflecting the day-to-day experiences of today’s
knowledge workers. This, along with the availability of increasingly complex and increasing
volumes of data means organisations need to improve their capability to manage data,
transition it into valuable information and knowledge that can be readily applied.
Today’s pharmaceutical operations are informed by an interconnected network of process
control systems, laboratory information systems, data and document management systems,
and enterprise management systems. These networks are processing, acting upon, and
highlighting information in a dynamic, immediate, and continuous manner. Scanning these
ecosystems for important signals, escalations, anomalies, and inconsistencies demands new
approaches and the application of new insights.
System and network design creates new layers of control and communication, requiring a
System of Systems (SoS) approach to assuring that the correct data flows and that data
analytics inform the appropriate and desired insights. The DIKW hierarchy and the RKI cycle
are not, in realty, pedestrian pathways. Rather they are superhighways of information that
must be rapidly interpreted into knowledge. Detecting trends or patterns, emergences, interrelationships and new insights (which are essential tools of systems thinking) and ‘seeing the
big picture’, all require access to the relevant information. KM can assure that the right
information flows to the right decision-makers, which is critical to the maintenance of system,
to process understanding, and to critical systems thinking (Mulholland & Greene, 2020).

Disclaimer
The views expressed in this article are those of the authors and not necessarily those of MSD.
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